| Serial Number | 98388195 |
| Word Mark | EPIWRITE |
| Filing Date | Friday, February 2, 2024 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, March 4, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, January 7, 2025 |
| Goods and Services | Pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pulmonary, renal, reproductive, respiratory, and skeletal diseases, and age-related diseases in the nature of arthritis, thyroid imbalance, heart disease, kidney disease, cancer, endocrine disorders, liver disease, obesity, skin, respiratory, gastrointestinal and dental disease |
| Goods and Services | Research and development in the field of pharmaceuticals, therapeutics, and biotechnology; Conducting research and clinical trials for others relating to pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pediatric, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases; Conducting research and clinical trials for others relating to veterinary pharmaceuticals in the fields of age-related, autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 29, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, February 29, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Moonwalk Biosciences |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | South San Francisco, CA 94080 |
| Party Name | Moonwalk Biosciences |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | South San Francisco, CA 94080 |
| Event Date | Event Description |
| Tuesday, February 6, 2024 | NEW APPLICATION ENTERED |
| Thursday, May 23, 2024 | NON-FINAL ACTION WRITTEN |
| Thursday, February 29, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, May 22, 2024 | ASSIGNED TO EXAMINER |
| Monday, August 19, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, August 19, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 23, 2024 | NON-FINAL ACTION E-MAILED |
| Thursday, May 23, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, August 19, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, August 27, 2024 | FINAL REFUSAL WRITTEN |
| Tuesday, August 27, 2024 | FINAL REFUSAL E-MAILED |
| Tuesday, August 27, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, October 30, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 30, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, October 30, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Thursday, December 12, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, December 12, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 12, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, December 12, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, December 12, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, January 1, 2025 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 7, 2025 | PUBLISHED FOR OPPOSITION |
| Tuesday, January 7, 2025 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 4, 2025 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |